Insmed (INSM) Q3 2024 earnings summary

Executive summary

• Achieved record global net revenues of $93.4 million in Q3 2024, up 18.2% year-over-year, driven by ARIKAYCE's double-digit growth across all regions.

• Expanded US sales force to 184, fully trained and deployed, supporting ARIKAYCE and upcoming brensocatib launch.

• Advanced late-stage pipeline with NDA filing for brensocatib on track for Q4 2024 and preparations for multiple phase 2 and 3 studies.

• Strengthened financial position through debt restructuring, equity raises, and increased cash reserves to $1.5 billion.

• Net loss for Q3 2024 was $220.5 million, compared to $158.9 million in Q3 2023.

Financial highlights

• Q3 2024 global net revenues reached $93.4 million, an 18.2% increase year-over-year, marking the highest quarterly sales for ARIKAYCE.

• US net revenue was $66.9 million (+13% YoY), Japan $21 million (+31% YoY), and Europe/ROW $5.6 million (+45% YoY).

• Cost of product revenues was $21.2 million (22.7% of revenues), consistent with historical performance.

• R&D expenses were $150.8 million; SG&A expenses were $118.9 million, reflecting investments in pipeline and commercial readiness.

• Cash, cash equivalents, and marketable securities totaled $1.5 billion at quarter end.

Outlook and guidance

• On track to achieve full-year 2024 global revenue guidance of $340–$360 million.

• Brensocatib NDA filing expected in Q4 2024; potential US launch mid-2025 pending FDA approval and priority review.

• Anticipate increased cash burn ahead of brensocatib revenue contribution due to launch preparations.

• Top-line results for Birch (CRS without nasal polyps) expected by end of 2025; Encore (ARIKAYCE) readout in Q1 2026.

• Phase 2 TPIP in PAH ongoing; topline results anticipated in H2 2025.